Depo-Provera

Contraception, endometriosis, menopausal vasomotor symptoms; hormonally-dependent, recurrent breast cancer in post-menopausal women. Adjunctive &/or palliative treatment of recurrent &/or metastatic endometrial or renal carcinoma.

IM Contraception 150 mg every 3 mth. Endometriosis 50 mg wkly or 100 mg every 2 wk for at least 6 mth. Menopausal vasomotor symptoms 150 mg every 12 wk. Recurrent &/or metastatic endometrial or renal cancer Initially 400-1,000 mg wkly then maintain at 400 mg mthly. Hormonally-dependent, recurrent breast cancer in postmenopausal women Initially 500 mg daily for 28 days then maintain at 500 mg twice wkly.

Hypersensitivity. Undiagnosed vag bleeding. Severe hepatic dysfunction. Known or suspected breast malignancy & pregnancy.

Discontinue use if meningioma is diagnosed. Not to be re-administered if sudden partial or complete loss of vision, sudden onset of proptosis, diplopia, migraine, papilloedema or retinal vascular lesions; jaundice develops. Not a protection against sexually transmitted infections eg, HIV. Not recommended in patients w/ history of VTE. Unexpected vag bleeding, degree of fluid retention, history of clinical depression treatment; meningioma, diabetic patients; loss of bone mineral density; osteoporotic risk factors eg, chronic alcoholism &/or tobacco use, chronic use of drugs reducing bone mass (eg, anticonvulsants or corticosteroids), low BMI or eating disorder (eg, anorexia nervosa or bulimia), metabolic bone disease, strong family history of osteoporosis; wt gain; breast & ovarian cancer; increased risk of CV events eg, MI, CHD, stroke, VTE; CAD; pulmonary embolism; dementia; Cushingoid symptoms; suppressed adrenal function. May decrease levels of endocrine biomarkers eg, plasma/urinary steroids & gonadotropins, sex hormone-binding-globulin; ACTH & hydrocortisone. Ensure adequate Ca & vit D intake. Long-term use. Hepatic & renal insufficiency. Prolonged anovulation w/ amenorrhoea &/or erratic menstrual patterns. Lactation. Not to be used in pre-menarche childn.

Nervousness; headache; abdominal pain & discomfort, nausea; increased/decreased wt; dysfunctional uterine bleeding. Depression, decreased libido, insomnia; dizziness, tremors; abdominal distention, vomiting, constipation; alopecia, acne, rash, urticaria, pruritus, hyperhidrosis; back pain; vag & cervical discharge, breast tenderness & pain, erectile dysfunction; fluid retention/oedema, asthenia, pyrexia, fatigue, inj site reaction, persistent atrophy/indentation/dimpling; drug hypersensitivity; increased appetite.

Depot Contraceptives

G03AC06 - medroxyprogesterone ; Belongs to the class of progestogens. Used as systemic contraceptives.

B